📢 #ESMO26 已来临；请留意我们的会议更新！
在本视频中，Dr @tnewsomdavis 将分享关于 HER2 导向 NSCLC 的最新进展，并介绍将出席 ESMO 的医学专家
➡️Drs @LizzySmyth1 & @YJanjigianMD：#Gastric/GEJ cancer
➡️ Assoc. Prof. Gerald Prager：#CRC & #PanCan
➡️ Prof. Hong Jae Chon & Assoc. Prof. Lorenza Rimassa：#HCC / #LiverCancer
➡️ Dr Louise Lim：#NSCLC
➡️ Dr @jhaveri_komal：#BreastCancer
➡️ Dr @DrIacovelli：#ProstateCancer & #BladderCancer
新数据对临床实践意味着什么？
🎬 请持续关注，以便在视频发布后第一时间观看：https://cor2ed.com/n-connect/programmes/highlights-from-esmo-2026/?media=0
胃/GEJ 癌更新由阿斯利康的独立教育资助支持。在西班牙，所显示的信息仅面向有权开具或配发药品的医疗专业人员。请勿在面向公众的媒体、支持材料或传播渠道中分发。HCC 和 HER2 导向 NSCLC 更新分别由 BeOne 和拜耳的独立教育资助支持。所有其他更新由 COR2ED 支持
所有内容仅供医疗专业人员参考
#MedEd #OncTwitter #MedTwitter #pcsm #lcsm
394 浏览 · 8 赞 · 8 转发 · 0 回复
Early clinical antitumor activity of VRN101099 across diverse HER2-mutants in solid tumors
https://esmocongress.esmo.orgHealth-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgEfficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgGene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers
https://esmocongress.esmo.org来源：COR2ED · x.com